Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jenny Ambrosino

Physician Assistant, Medical Richmond, VA Physician Assistant

NPI 1487175089 CMS profile 10800876

15 W 7Th St Apt 505, Richmond, VA 23224

Open in the dashboard

General payments

$7,114

374 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenny Ambrosino of Richmond, VA is reported in the CMS Open Payments database as having received $7,114 across 374 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $532 4
2024 General $733 9
2023 General $2,227 124
2022 General $1,764 111
2021 General $1,858 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenny Ambrosino
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jenny Ambrosino were reported at $532. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jenny Ambrosino Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,858 $156 $41–$563 $132
2022 $1,764 $185 $55–$649 $149
2023 $2,227 $199 $58–$717 $160
2024 $733 $206 $62–$740 $164
2025 $532 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,471 98 payments
  2. Medtronic, Inc. $828 10 payments
  3. Novo Nordisk Inc $569 38 payments
  4. Lilly USA, LLC $423 32 payments
  5. AstraZeneca Pharmaceuticals LP $325 23 payments
  6. Pfizer Inc. $254 14 payments
  7. GlaxoSmithKline, LLC. $233 11 payments
  8. Amarin Pharma Inc. $230 13 payments
  9. Otsuka America Pharmaceutical, Inc. $223 12 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $221 12 payments
  11. Other $2,338 111 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,490 369 payments
  2. Travel and Lodging $503 3 payments
  3. Education $121 2 payments
Products named General payments · program years 2021–2025
  1. INTERSTIM $828 10 payments
  2. UBRELVY $585 39 payments
  3. VRAYLAR $572 39 payments
  4. NURTEC ODT $362 19 payments
  5. QULIPTA $317 20 payments
  6. Ozempic $274 18 payments
  7. RYBELSUS $255 17 payments
  8. Vascepa $230 13 payments
  9. REXULTI $223 12 payments
  10. TRULICITY $206 16 payments
  11. Other $4,522 258 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

392

Median for Physician Assistant: 241

Drug cost

$15,678

Median for Physician Assistant: $4,110

Branded share of claims

10.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 18 $9,084
Estradiol Generic 20 $1,282
Methenamine Hippurate Generic 19 $1,020
Trospium Chloride Generic 12 $842
Rosuvastatin Calcium Generic 67 $618
Atorvastatin Calcium Generic 44 $595
Tamsulosin Hcl Generic 43 $361
Esomeprazole Magnesium Generic 11 $351
Montelukast Sodium Generic 15 $334
Testosterone Cypionate Generic 12 $304

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$15,919

Medicare's payments for the services billed

Medicare patients

132

Average age 70

Services billed

399

58 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 55%
Ischemic heart disease 36%
Diabetes 33%
Chronic kidney disease 33%
Cancer 27%
Depression 24%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

374 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record